Hatch Medical to Broker New Biopsy Technology
Atlanta, Georgia – Medical device incubator and technology
brokerage firm, Hatch Medical, L.L.C. (www.hatchmedical.com)
recently announced that FNA Concepts, L.L.C.’s patent-pending, automated fine
needle aspiration biopsy instrument has become their newest project.
“FNA Concepts’ technology fully automates what
was once an operator-dependent, manual procedure, improving both diagnostic
accuracy and reproducibility. Although
full-core needle biopsies have become widely accepted, fine needle aspirated
biopsies remain the predominate method used for diagnosing early-stage cancers
in soft tissue throughout the world,” commented Paul Gianneschi, President and
CEO of Hatch Medical, LLC.
Leopold Kaplan, M.D., FNA Concepts’ President
added, “We are pleased to have Hatch Medical as our exclusive agent, and look
forward to identifying a commercial partner committed to bringing this exciting
new technology to market”
FNA Concepts’ device incorporates technology which
mimics current hand held methods, yet improves upon the overall accuracy,
reproducibility and speed of the procedure.
Because this new technology utilizes small bore needles of 20 - 27 guage,
it is ideally suited to address the needs of physicians performing breast,
thyroid and lung, as well as other soft tissue, biopsies.
These markets alone represent over 5,000,000 procedures annually.
This technology is available for sale or license to
interested third parties through an exclusive agreement with Hatch Medical.
Please direct all inquiries to Paul Gianneschi at Hatch Medical via
e-mail: pgianneschi@hatchmedical.com
or by dialing: 770-982-6306.
In a separate news item, Hatch Medical announced the
addition of Steven Hvozda to its executive team. Mr. Hvozda will join Hatch Medical as an Executive Vice
President and will focus on business development.
“Steve is a seasoned professional that brings
exceptional experience and depth to our organization.
A 12-year veteran of the industry, Steve led VasCath’s tremendous
growth in the venous access market as their Director of Marketing.
Following CR Bard, Inc.’s acquisition, Steve served in a variety of
senior management roles at Bard’s Peripheral Technologies Division, and was
most recently Global Director of Sales and Marketing at Bard’s Carotid
Endovascular Systems Group,” commented Mr. Gianneschi.
“I am
pleased to be joining an aggressive, market oriented company focused on meeting
the needs of physician inventors, device organizations and patients,” said Mr.
Hvozda.
Hatch
Medical brokers and jointly develops minimally invasive medical devices for the
diagnosis and treatment of vascular and oncological disease through its network
of product development experts. Hatch
Medical team members include intellectual property and transactional attorneys,
biomedical engineers, regulatory affairs consultants, marketing and business
development executives, medical device manufacturers, university teaching
hospitals and leading physicians.
Through Hatch Medical’s unique risk-sharing
program, product development team members exchange services and resources for
equity in physician conceived projects. This
structure enables the physician inventor to benefit from the services of
industry experts without paying upfront costs or out-of-pocket expenses, while
maintaining meaningful equity.
For additional information contact Hatch Medical,
L.L.C., Paul Gianneschi, 770-982-6306, fax: 770-982-9090 or e-mail:
pgianneschi@hatchmedical.com.
CONTACT:
Hatch Medical, L.L.C.
Paul Gianneschi, 770-982-6306
Hatch Medical,
L.L.C.
Duluth, GA 30097
Phone: 770-476-9940
Facsimile: 770-476-7740
info@hatchmedical.com
© 2001 - 2008 Hatch Medical, L.L.C. - All rights reserved